Study of Gilead’s remdesivir shows improvement in moderate cases
Read full post at forexlive.com
Results of the latest study
Gilead released its of patients with moderate COVID-19 and reported that patients on a 5-day tready were “65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group.”
Gilead released its of patients with moderate COVID-19 and reported that patients on a 5-day tready were “65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group.”